Digestive Diseases

General Treatment Considerations

Supportive Therapy in IBD: What Additional Diagnoses and Conditions Must Be Treated?

Swoger J.M. · Binion D.G.

Author affiliations

Division of Gastroenterology, Hepatology and Nutrition, UPMC Inflammatory Bowel Disease Center, University of Pittsburgh School of Medicine, Pittsburgh, Pa., USA

Keywords: Non-steroidal anti-inflammatory drugsPainSleep deprivationUlcerative colitisClostridium difficileCrohn’s diseaseDrug hypersensitivityHypercoagulability

Related Articles for ""
Dig Dis 2010;28:452–462
https://doi.org/10.1159/000320402

Log in to MyKarger to check if you already have access to this content.




Forgot your password
Sign up to MyKarger

Buy

  • FullText & PDF
  • Unlimited re-access via MyKarger
  • Unrestricted printing, no saving restrictions for personal use
read more
CHF 38.00 *
EUR 35.00 *
USD 39.00 *

Select

KAB

Buy a Karger Article Bundle (KAB) and profit from a discount!


If you would like to redeem your KAB credit, please log in.

Save over 20% compared to the individual article price.

Learn more

Rent/Cloud

  • Rent for 48h to view
  • Buy Cloud Access for unlimited viewing via different devices
  • Synchronizing in the ReadCube Cloud
  • Printing and saving restrictions apply
Rental: USD 8.50
Cloud: USD 20.00

Select

Subscribe

  • Access to all articles of the subscribed year(s) guaranteed for 5 years
  • Unlimited re-access via Subscriber Login or MyKarger
  • Unrestricted printing, no saving restrictions for personal use
read more

Subcription rates

Select
* The final prices may differ from the prices shown due to specifics of VAT rules.

Article / Publication Details

First-Page Preview
Abstract of General Treatment Considerations

Published online: September 30, 2010
Issue release date: October 2010

Number of Print Pages: 11
Number of Figures: 0
Number of Tables: 0

ISSN: 0257-2753 (Print)
eISSN: 1421-9875 (Online)

For additional information: https://www.karger.com/DDI

Abstract

Despite advances in our understanding of inflammatory bowel disease (IBD) pathogenesis and increased ability to treat patients with severe and refractory disease, patients continue to suffer from disease complications, and increasing numbers of both Crohn’s disease (CD) and ulcerative colitis (UC) patients are admitted annually in the USA. The rapid evolution in IBD medications and treatment paradigms has contributed to a disparity in clinical care which may vary between expert centers routinely treating large numbers of IBD patients and hospitals with low annual IBD admissions. High-volume centers handling in excess of 150 IBD annual admissions have improved operative and inpatient outcomes compared with hospitals caring for IBD patients less frequently. Although the precise reason for this disparity in clinical outcomes is not known, we hypothesize that expert centers provide superior IBD supportive therapy. This supportive care includes additional diagnostic and therapeutic approaches to help patients achieve optimal outcomes. We review information regarding disparities in the quality of IBD clinical care then focus on supportive therapy for IBD patients, including diagnostic approaches to identify confounding factors contributing to poor IBD outcome, supportive therapeutic approaches to optimize the outcome in hospitalized IBD patients, and future directions exploring brain-body interaction in the treatment of pain, stress and sleep deprivation in patients suffering from IBD.

© 2010 S. Karger AG, Basel



Related Articles:

References

  1. Baumgart DC, Sandborn WJ: Inflammatory bowel disease: clinical aspects and established and evolving therapies. Lancet 2007;369:1641–1657.
    External Resources
  2. Bewtra M, Su C, Lewis JD: Trends in hospitalization rates for inflammatory bowel disease in the United States. Clin Gastroenterol Hepatol 2007;5:597–601.
    External Resources
  3. Ananthakrishnan AN, Issa M, Beaulieu DB, et al: History of medical hospitalization predicts future need for colectomy in patients with ulcerative colitis. Inflamm Bowel Dis 2009;15:176–181.
    External Resources
  4. Nguyen GC, Steinhart AH: Nationwide patterns of hospitalizations to centers with high volume of admissions for inflammatory bowel disease and their impact on mortality. Inflamm Bowel Dis 2008;14:1688–1694.
    External Resources
  5. Kaplan GG, McCarthy EP, Ayanian JZ, et al: Impact of hospital volume on postoperative morbidity and mortality following a colectomy for ulcerative colitis. Gastroenterology 2008;134:680–687.
    External Resources
  6. Kappelman MD, et al: Quality of care in inflammatory bowel disease: a review and discussion. Inflamm Bowel Dis 2010;16:125–133.
    External Resources
  7. Ananthakrishnan AN, McGinley EL, Binion DG: Does it matter where you are hospitalized for inflammatory bowel disease? A nationwide analysis of hospital volume. Am J Gastroenterol 2008;103:2789–2798.
    External Resources
  8. Esrailian E, Spiegel BM, Targownik LE, et al: Differences in the management of Crohn’s disease among experts and community providers, based on a national survey of sample case vignettes. Aliment Pharmacol Ther 2007;26:1005–1018.
    External Resources
  9. Kornbluth A, Sachar DB: Ulcerative colitis practice guidelines in adults: American College Of Gastroenterology, Practice Parameters Committee. Am J Gastroenterol 2010;105:501–523; quiz 524.
    External Resources
  10. Schroeder KW, Tremaine WJ, Ilstrup DM: Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis: a randomized study. N Engl J Med 1987;317:1625–1629.
    External Resources
  11. Sturgeon JB, Bhatia P, Hermens D, Miner PB Jr: Exacerbation of chronic ulcerative colitis with mesalamine. Gastroenterology 1995;108:1889–1893.
    External Resources
  12. Cross RK, Wilson KT, Binion DG: Polypharmacy and Crohn’s disease. Aliment Pharmacol Ther 2005;21:1211–1216.
    External Resources
  13. Sewitch MJ, Abrahamowicz M, Barkun A, et al: Patient nonadherence to medication in inflammatory bowel disease. Am J Gastroenterol 2003;98:1535–1544.
    External Resources
  14. Werlin SL, Grand RJ: Bloody diarrhea: a new complication of sulfasalazine. J Pediatr 1978;92:450–451.
    External Resources
  15. Bajaj JS, Saeian K, Varma RR, et al: Increased rates of early adverse reaction to azathioprine in patients with Crohn’s disease compared to autoimmune hepatitis: a tertiary referral center experience. Am J Gastroenterol 2005;100:1121–1125.
    External Resources
  16. Ananthakrishnan AN, Attila T, Otterson MF, et al: Severe pulmonary toxicity after azathioprine/6-mercaptopurine initiation for the treatment of inflammatory bowel disease. J Clin Gastroenterol 2007;41:682–688.
    External Resources
  17. Bartlett JG, Moon N, Chang TW, Taylor N, Onderdonk AB: Role of Clostridium difficile in antibiotic-associated pseudomembranous colitis. Gastroenterology 1978;75:778–782.
    External Resources
  18. Ananthakrishnan AN, Issa M, Binion DG: Clostridium difficile and inflammatory bowel disease. Gastroenterol Clin North Am 2009;38:711–728.
    External Resources
  19. Bartlett JG, Perl TM: The new Clostridium difficile: what does it mean? N Engl J Med 2005;353:2503–2505.
    External Resources
  20. McDonald LC, Owings M, Jernigan DB: Clostridium difficile infection in patients discharged from US short-stay hospitals, 1996–2003. Emerg Infect Dis 2006;12:409–415.
    External Resources
  21. Ananthakrishnan AN, McGinley EL, Binion DG: Excess hospitalisation burden associated with Clostridium difficile in patients with inflammatory bowel disease. Gut 2008;57:205–210.
    External Resources
  22. Nguyen GC, Kaplan GG, Harris ML, Brant SR: A national survey of the prevalence and impact of Clostridium difficile infection among hospitalized inflammatory bowel disease patients. Am J Gastroenterol 2008;103:1443–1450.
    External Resources
  23. Issa M, Vijayapal A, Graham MB, et al: Impact of Clostridium difficile on inflammatory bowel disease. Clin Gastroenterol Hepatol 2007;5:345–351.
    External Resources
  24. Rodemann JF, Dubberke ER, Reske KA, Seo da H, Stone CD: Incidence of Clostridium difficile infection in inflammatory bowel disease. Clin Gastroenterol Hepatol 2007;5:339–344.
    External Resources
  25. Bolton RP, Sherriff RJ, Read AE: Clostridium difficile associated diarrhoea: a role in inflammatory bowel disease? Lancet 1980;1:383–384.
    External Resources
  26. Trnka YM, LaMont JT: Association of Clostridium difficile toxin with symptomatic relapse of chronic inflammatory bowel disease. Gastroenterology 1981;80:693–696.
    External Resources
  27. Hyams JS, McLaughlin JC: Lack of relationship between Clostridium difficile toxin and inflammatory bowel disease in children. J Clin Gastroenterol 1985;7:387–390.
    External Resources
  28. Jodorkovsky D, Young Y, Abreu MT: Clinical outcomes of patients with ulcerative colitis and co-existing Clostridium difficile infection. Dig Dis Sci 2010;55:415–420.
    External Resources
  29. Ben-Horin S, Margalit M, Bossuyt P, et al: Combination immunomodulator and antibiotic treatment in patients with inflammatory bowel disease and Clostridium difficile infection. Clin Gastroenterol Hepatol 2009;7:981–987.
    External Resources
  30. Pascarella F, Martinelli M, Miele E, et al: Impact of Clostridium difficile infection on pediatric inflammatory bowel disease. J Pediatr 2009;154:854–858.
    External Resources
  31. Nemat H, Khan R, Ashraf MS, et al: Diagnostic value of repeated enzyme immunoassays in Clostridium difficile infection. Am J Gastroenterol 2009;104:2035–2041.
    External Resources
  32. Issa M, Ananthakrishnan AN, Binion DG: Clostridium difficile and inflammatory bowel disease. Inflamm Bowel Dis 2008;14:1432–1442.
    External Resources
  33. Ricciardi R, Ogilvie JW Jr, Roberts PL, et al: Epidemiology of Clostridium difficile colitis in hospitalized patients with inflammatory bowel diseases. Dis Colon Rectum 2009;52:40–45.
    External Resources
  34. Hatoum OA, Binion DG: The vasculature and inflammatory bowel disease: contribution to pathogenesis and clinical pathology. Inflamm Bowel Dis 2005;11:304–313.
    External Resources
  35. Hatoum OA, Spinelli KS, Abu-Hajir M, et al: Mesenteric venous thrombosis in inflammatory bowel disease. J Clin Gastroenterol 2005;39:27–31.
    External Resources
  36. Fichera A, Cicchiello LA, Mendelson DS, et al: Superior mesenteric vein thrombosis after colectomy for inflammatory bowel disease: a not uncommon cause of postoperative acute abdominal pain. Dis Colon Rectum 2003;46:643–648.
    External Resources
  37. Nguyen GC, Sam J: Rising prevalence of venous thromboembolism and its impact on mortality among hospitalized inflammatory bowel disease patients. Am J Gastroenterol 2008;103:2272–2280.
    External Resources
  38. Ananthakrishnan AN, McGinley EL, Binion DG: Inflammatory bowel disease in the elderly is associated with worse outcomes: a national study of hospitalizations. Inflamm Bowel Dis 2009;15:182–189.
    External Resources
  39. Gibbs J, Cull W, Henderson W, et al: Preoperative serum albumin level as a predictor of operative mortality and morbidity: results from the National VA Surgical Risk Study. Arch Surg 1999;134:36–42.
    External Resources
  40. Bielefeldt K, Davis B, Binion DG: Pain and inflammatory bowel disease. Inflamm Bowel Dis 2009;15:778–788.
    External Resources
  41. Kefalakes H, Stylianides TJ, Amanakis G, Kolios G: Exacerbation of inflammatory bowel diseases associated with the use of nonsteroidal anti-inflammatory drugs: myth or reality? Eur J Clin Pharmacol 2009;65:963–970.
    External Resources
  42. Cipolla G, Crema F, Sacco S, et al: Nonsteroidal anti-inflammatory drugs and inflammatory bowel disease: current perspectives. Pharmacol Res 2002;46:1–6.
    External Resources
  43. Reinisch W, Miehsler W, Dejaco C, et al: An open-label trial of the selective cyclo-oxygenase-2 inhibitor, rofecoxib, in inflammatory bowel disease-associated peripheral arthritis and arthralgia. Aliment Pharmacol Ther 2003;17:1371–1380.
    External Resources
  44. Hatoum OA, Binion DG, Otterson MF, Gutterman DD: Acquired microvascular dysfunction in inflammatory bowel disease: loss of nitric oxide-mediated vasodilation. Gastroenterology 2003;125:58–69.
    External Resources
  45. King CR, Knutson KL, Rathouz PJ, et al: Short sleep duration and incident coronary artery calcification. JAMA 2008;300:2859–2866.
    External Resources
  46. Keefer L, Stepanski EJ, Ranjbaran Z, et al: An initial report of sleep disturbance in inactive inflammatory bowel disease. J Clin Sleep Med 2006;2:409–416.
    External Resources
  47. Ranjbaran Z, Keefer L, Farhadi A, et al: Impact of sleep disturbances in inflammatory bowel disease. J Gastroenterol Hepatol 2007;22:1748–1753.
    External Resources
  48. Ranjbaran Z, Keefer L, Stepanski E, Farhadi A, Keshavarzian A: The relevance of sleep abnormalities to chronic inflammatory conditions. Inflamm Res 2007;56:51–57.
    External Resources
  49. Szigethy E, Craig AE, Iobst EA, et al: Profile of depression in adolescents with inflammatory bowel disease: implications for treatment. Inflamm Bowel Dis 2009;15:69–74.
    External Resources
  50. Tang Y, Preuss F, Turek FW, Jakate S, Keshavarzian: Sleep deprivation worsens inflammation and delays recovery in a mouse model of colitis. Sleep Med 2009;10:597–603.
    External Resources
  51. Delaney CP, Dadvand B, Remzi FH, Church JM, Fazio VW: Functional outcome, quality of life, and complications after ileal pouch-anal anastomosis in selected septuagenarians. Dis Colon Rectum 2002;45:890–894; discussion 894.
    External Resources
  52. Szigethy E, Hardy D, Craig AE, Low C, Kukic S: Girls connect: effects of a support group for teenage girls with inflammatory bowel disease and their mothers. Inflamm Bowel Dis 2009;15:1127–1128.
    External Resources
  53. Szigethy E, Kenney E, Carpenter J, et al: Cognitive-behavioral therapy for adolescents with inflammatory bowel disease and subsyndromal depression. J Am Acad Child Adolesc Psychiatry 2007;46:1290–1298.
    External Resources
  54. Su C, Lichtenstein GR, Krok K, Brensinger CM, Lewis JD: A meta-analysis of the placebo rates of remission and response in clinical trials of active Crohn’s disease. Gastroenterology 2004;126:1257–1269.
    External Resources
  55. Su C, Lewis JD, Goldberg B, Brensinger C, Lichtenstein GR: A meta-analysis of the placebo rates of remission and response in clinical trials of active ulcerative colitis. Gastroenterology 2007;132:516–526.
    External Resources
  56. Sandborn WJ, Colombel JF, Enns R, et al: Natalizumab induction and maintenance therapy for Crohn’s disease. N Engl J Med 2005;353:1912–1925.
    External Resources
  57. Valentine JF, Fedorak RN, Feagan B, et al: Steroid-sparing properties of sargramostim in patients with corticosteroid-dependent Crohn’s disease: a randomised, double-blind, placebo-controlled, phase 2 study. Gut 2009;58:1354–1362.
    External Resources
  58. Walsh BA, Grunert BK, Telford GL, Otterson MF: Multidisciplinary management of altered body image in the patient with an ostomy. J Wound Ostomy Continence Nurs 1995;22:227–236.
    External Resources

Article / Publication Details

First-Page Preview
Abstract of General Treatment Considerations

Published online: September 30, 2010
Issue release date: October 2010

Number of Print Pages: 11
Number of Figures: 0
Number of Tables: 0

ISSN: 0257-2753 (Print)
eISSN: 1421-9875 (Online)

For additional information: https://www.karger.com/DDI

Copyright / Drug Dosage / Disclaimer

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

Article Tools
Article Details

2010, Vol.28, No. 3

October 2010

Article

Recommend This
TOP